neoadjuvant durvalumab shows benefit in triple-negative breast cancer
Published 4 years ago • 384 plays • Length 1:08Download video MP4
Download video MP3
Similar videos
-
0:53
keynote-522 demonstrates potential for immunotherapy in triple-negative breast cancer
-
2:52
neoadjuvant and adjuvant therapy in triple negative breast cancer
-
3:12
neoadjuvant versus adjuvant therapy in tnbc
-
1:17
neoadjuvant immunotherapy in tnbc and targeted lnd in breast cancer: 2023 best of breast conference
-
2:10
testing and targeted therapy in triple negative breast cancer: 2023 west oncology
-
27:03
triple negative breast cancer: predictive and prognostic biomarkers for neo/adjuvant therapy
-
1:30
begonia: durvalumab combinations in advanced tnbc
-
5:54
case 3: treatment after progression in triple-negative breast cancer
-
0:48
dr. william sikov on triple-negative breast cancer patients not responding to treatment
-
12:47
neoadjuvant treatment in triple-negative breast cancer
-
1:00
overcoming challenges in treating patients with triple-negative breast cancer
-
2:25
new technology allows important discovery in triple negative breast cancer
-
1:14
the importance of a biomarker-directed approach in triple-negative breast cancer
-
1:03
new directions in immunotherapy for improving outcomes in tnbc
-
5:49
neoadjuvant treatment for triple-negative breast cancer
-
3:50
clinical approach to triple-negative breast cancer
-
3:47
chemotherapy plus durvalumab in triple negative breast cancer
-
1:58
targeted therapy in tnbc
-
1:13
predictive markers of response to durvalumab w/nab-paclitaxel doxorubicin/cyclophosphamide in tnbc